New Deuruxolitinib Data to Be Presented at EADV
09/25/2024
Sun Pharma will present new clinical data on the JAK1/JAK2 inhibitor deuruxolitinib at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands from September 25-28, the company announced.
Deuruxolitinib, which Sun Pharma provides under the name LEQSELVI™, was recently approved by the FDA and is showing promising results in treating severe alopecia areata, the company said in a press release.
EADV content on the drug will include:
- Podium Presentation: A greater proportion (95%) of patients taking deuruxolitinib 8 mg twice a day showed improvement in their hair satisfaction scores, compared to baseline over the 24-week period. Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials (Presentation Time: September 26 at 16:30-16:40)
- Poster Presentation: Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- Poster Presentation: Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial.